Clik here to view.
武田薬品、米国FDAが高リスク骨髄異形成症候群（HR-MDS）患者を治療するPevonedistatを画期的治療薬に指定したと発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
武田宣布，美国FDA认证Pevonedistat为用于治疗较高危骨髓异常增生综合征(HR-MDS)患者的突破性治疗药物
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical...
CAMBRIDGE, Mass. Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading...
View ArticleClik here to view.
拓臻生物宣布已完成开发用于NASH的SSAO抑制剂TERN-201的1期临床试验并取得阳性成果
加州福斯特城和上海 (美国商业资讯)–专注于发现和开发肝病和癌症创新治疗药物的全球性生物制药公司拓臻生物（Terns Pharmaceuticals,...
View ArticleClik here to view.
武田宣布2020财年第一季度业绩；确认管理层指引，并提高全年列报运营利润和列报净利润
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on...
WILMINGTON, Del. Incyte (Nasdaq: INCY) today reports 2020 second quarter financial results, and provides a status update on the Company’s development portfolio. “We continue to execute successfully...
View ArticleClik here to view.
Cellix Bio Pharma Completes the Acquisition of Avaca Pharma
HYDERABAD, India Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support,...
View ArticleClik here to view.
Evaluate新レポート：COVID-19パンデミック下でさえ、革新的で有効な治療薬に対する需要は続く
ロンドン & ボストン & 東京 （ビジネスワイヤ） — –ライフサイエンス分野における信頼性の高いマーケット情報および分析を2026年までの独自のコンセンサス予測とともに提供するエバリュエートが、2020年7月16日に発行した「EvaluatePharma® ワールドプレビュー2020 2026年への展望」第13版（原文：英語）の日本語版をリリースしたことをお知らせします。...
View ArticleClik here to view.
Vyripharm International, Inc. and the National Yang-Ming University Signed a...
HOUSTON Vyripharm International, Inc. (VI), is a subsidiary of Vyripharm Enterprises, LLC, a privately held company formed for Partnerships and Joint Ventures with International Public or Private...
View ArticleClik here to view.
The China Center for Drug Evaluation, National Medical Products...
SOMERSET, N.J. Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough...
View ArticleClik here to view.
Humanigen Appoints Bob Atwill as Head of Asia-Pacific Region
BURLINGAME, Calif. Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the company’s...
View ArticleClik here to view.
Crown Bioscience Signals Increased Investment in Digital Transformation with...
SAN DIEGO Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations,...
View ArticleClik here to view.
CANbridge Pharmaceuticals Receives Marketing Approval for NERLYNX®...
BEIJING & SHANGHAI CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions, announced that it has received...
View ArticleClik here to view.
Crown Bioscienceは新たな最高執行責任者を任命し、デジタルトランスフォーメーションへの投資を強化
サンディエゴ発 Crown Bioscienceは本日、John Guを最高執行責任者に任命したことを発表した。 Guはデジタル化に関する深い専門知識を活用して生産性を向上させ、CrownBioのグローバルオペレーション全体でリーダーシップを発揮する。...
View ArticleClik here to view.
随着新首席运营官的上任，中美冠科在数字化转型方面的投资将有所增加
加州圣地亚哥 中美冠科今天宣布John Gu担任我们新的首席运营官。John将在中美冠科的全球业务中发挥领导作用，他将利用他在数字化方面深厚的专业知识来提高冠科的创造力。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20200806005032/zh-CN/ Crown Bioscience Chief...
View ArticleClik here to view.
Terns Pharmaceuticals Appoints Senthil Sundaram as Chief Executive Officer,...
FOSTER CITY, Calif. Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, announced today the...
View ArticleClik here to view.
Novocellbio in Korea Confirms NOVO-NK’s Promising Antiviral Effects Against...
INCHEON, South Korea Novocellbio Co., Ltd. conducted experiments using “NOVO-NK”, an autologous natural killer cell treatment at Seoul National University College of Medicine. It was confirmed that...
View ArticleClik here to view.
Terns...
米カリフォルニア州フォスターシティ （ビジネスワイヤ） — 肝疾患を治療するベストインクラスの単剤療法および併用療法の開発に傾注するバイオ製薬企業のTerns Pharmaceuticals, Inc....
View ArticleClik here to view.
ソレイジア・ファーマ：新規開発品SP-05の日本における独占的開発販売権導入契約締結のお知らせ
東京 （ビジネスワイヤ） — ソレイジア・ファーマ株式会社は、本日、Isofol Medical AB（STO：ISOFOL、本社：スウェーデン、CEO：Ulf...
View ArticleClik here to view.
Seoul Viosys to Develop a Cancer Diagnosis Technology for Companion Animals...
ANSAN, South Korea Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that it has developed an advanced concept technology for early diagnosis of cancer in...
View Article